These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 18452422)

  • 21. [Hypoprotidemia may explain imatinib intoxication in a patient with Philadelphia-positive acute lymphoblastic leukemia].
    Gaïes E; Trabelsi S; Sahnoun R; Salouage I; Jebabli N; Charfi R; Lakhal M; Hdiji S; Klouz A
    Therapie; 2013; 68(2):125-7. PubMed ID: 23773356
    [No Abstract]   [Full Text] [Related]  

  • 22. Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib.
    Loglisci G; Breccia M; Nanni M; Mancini M; De Cuia R; Cannella L; Salaroli A; Federico V; Serrao A; Loglisci MG; Santopietro M; Alimena G
    Leuk Lymphoma; 2011 Jul; 52(7):1372-5. PubMed ID: 21463110
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy of dasatinib in conjunction with alpha-interferon for the treatment of imatinib-resistant and dasatinib-resistant Ph+ acute lymphoblastic leukemia.
    Visani G; Piccaluga P; Malagola M; Isidori A
    Leukemia; 2009 Sep; 23(9):1687-8. PubMed ID: 19421228
    [No Abstract]   [Full Text] [Related]  

  • 24. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
    Ottmann OG; Wassmann B; Pfeifer H; Giagounidis A; Stelljes M; Dührsen U; Schmalzing M; Wunderle L; Binckebanck A; Hoelzer D;
    Cancer; 2007 May; 109(10):2068-76. PubMed ID: 17429836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
    Soverini S; Martinelli G; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M
    J Clin Oncol; 2006 Nov; 24(33):e51-2. PubMed ID: 17114651
    [No Abstract]   [Full Text] [Related]  

  • 26. Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events.
    Shayani S
    Ther Drug Monit; 2010 Dec; 32(6):680-7. PubMed ID: 20864900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maintenance therapy with dasatinib after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Teng CL; Yu JT; Chen HC; Hwang WL
    Ann Hematol; 2013 Aug; 92(8):1137-9. PubMed ID: 23307602
    [No Abstract]   [Full Text] [Related]  

  • 28. [Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease].
    Hochhaus A
    Dtsch Med Wochenschr; 2002 Mar; 127(9):451-6. PubMed ID: 11870560
    [No Abstract]   [Full Text] [Related]  

  • 29. Haemorrhagic complications associated with reduced alpha2-plasmin inhibitor during imatinib use in a patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Matsue K; Aoki T; Odawara J; Kimura S; Yamakura M; Takeuchi M
    Leuk Res; 2009 Jun; 33(6):867-9. PubMed ID: 18951628
    [No Abstract]   [Full Text] [Related]  

  • 30. Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Caocci G; Vacca A; Ledda A; Murgia F; Piras E; Greco M; Arras M; Atzeni S; Littera R; La Nasa G
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):652-4. PubMed ID: 22240733
    [No Abstract]   [Full Text] [Related]  

  • 31. Pneumatosis intestinalis and imatinib mesylate.
    O'Rafferty C; McElligott F; Storey L; O'Marcaigh A; Smith O
    Ann Hematol; 2014 Oct; 93(10):1783-4. PubMed ID: 24647683
    [No Abstract]   [Full Text] [Related]  

  • 32. Dasatinib induces long-term remission in imatinib-resistant Philadelphia chromosome-positive acute megakaryoblastic leukemia but fails to prevent development of central nervous system progression.
    Papageorgiou SG; Pappa V; Economopoulou C; Tsirigotis P; Konsioti F; Ionnidou ED; Chondropoulos S; Vasilatou D; Papageorgiou E; Economopoulos T; Dervenoulas J
    Leuk Res; 2010 Sep; 34(9):e254-6. PubMed ID: 20392492
    [No Abstract]   [Full Text] [Related]  

  • 33. Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Joseph Brandwein.
    Brandwein J
    Drugs; 2007; 67(17):2655. PubMed ID: 18034600
    [No Abstract]   [Full Text] [Related]  

  • 34. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Gruber F; Mustjoki S; Porkka K
    Br J Haematol; 2009 Jun; 145(5):581-97. PubMed ID: 19388927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase].
    Vinogradova OIu; Turkina AG; Vorontsova AV; Chelysheva EIu; Gusarova GA; Kuznetsov SV; Goriacheva SR; Sokolova MA; Abakumov EM; Stakhina OV; Domracheva EV; Misiurin AV; Khoroshko ND
    Ter Arkh; 2009; 81(7):41-6. PubMed ID: 19708572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Dasatinib. A novel tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia].
    Bjerrum OW; Dufva IH; Stentoft J; Hasselbalch HC
    Ugeskr Laeger; 2008 Jan; 170(5):331-3. PubMed ID: 18252160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential transient novel chromosomal translocations in a patient with chronic myelogenous leukemia in complete cytogenetic remission after therapy with imatinib mesylate.
    Papaioannou G; Athanasiadou A; Voutiadou G; Gaitatzi M; Batsis I; Touloumenidou T; Anagnostopoulos A
    Cancer Genet; 2011 Dec; 204(12):692-3. PubMed ID: 22285023
    [No Abstract]   [Full Text] [Related]  

  • 38. Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report.
    Taçoy G; Çengel A; Özkurt ZN; Türkoğlu S
    Turk Kardiyol Dern Ars; 2015 Jan; 43(1):78-81. PubMed ID: 25655855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
    Millot F; Cividin M; Brizard F; Chomel JC; Méchinaud F; Guilhot F
    Pediatr Blood Cancer; 2009 Jul; 52(7):891-2. PubMed ID: 19202569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficacy and safety of tyrosine kinase inhibitor dasatinib plus chemotherapy in the treatment of childhood Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Guo Y; Liu TF; Yang WY; Wang SC; Ruan M; Chen XJ; Zhang L; Liu F; Zou Y; Zhu XF
    Zhongguo Dang Dai Er Ke Za Zhi; 2015 Jun; 17(6):634-7. PubMed ID: 26108329
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.